Suppr超能文献

GPR75:去孤儿化研究进展、挑战及作为疾病治疗新药物靶点的潜力

GPR75: Advances, Challenges in Deorphanization, and Potential as a Novel Drug Target for Disease Treatment.

作者信息

Han Jingyi, Li Jiaojiao, Yao Sirui, Wei Zao, Jiang Hui, Xu Tao, Zeng Junwei, Xu Lin, Han Yong

机构信息

Department of Physiology, Zunyi Medical University, Zunyi 563006, China.

Department of Immunology, Zunyi Medical University, Zunyi 563006, China.

出版信息

Int J Mol Sci. 2025 Apr 25;26(9):4084. doi: 10.3390/ijms26094084.

Abstract

G protein-coupled receptor 75 (GPR75), a novel member of the rhodopsin-like G protein-coupled receptor (GPCR) family, has been identified across various tissues and organs, where it contributes to biological regulation and disease progression. Recent studies suggest potential interactions between GPR75 and ligands such as 20-hydroxyeicosatetraenoic acid (20-HETE) and C-C motif chemokine ligand 5 (CCL5/RANTES); however, its definitive endogenous ligand remains unidentified, and GPR75 is currently classified as an orphan receptor by International Union of Basic and Clinical Pharmacology (IUPHAR). Research on GPR75 deorphanization has underscored its critical roles in disease models, particularly in metabolic health, glucose regulation, and stability of the nervous and cardiovascular systems. However, the signaling pathways of GPR75 across different pathological conditions require further investigation. Importantly, ongoing studies are targeting GPR75 for drug development, exploring small molecule inhibitors, antibodies, and gene silencing techniques, positioning GPR75 as a promising GPCR target for treating related diseases. This review summarizes the recent advancements in GPR75 deorphanization research, examines its functions across tissues and systems, and highlights its links to metabolic, cardiovascular, and neurological disorders, thereby providing a resource for researchers to better understand the biological functions of this receptor.

摘要

G蛋白偶联受体75(GPR75)是视紫红质样G蛋白偶联受体(GPCR)家族的一个新成员,已在各种组织和器官中被鉴定出来,它在其中参与生物调节和疾病进展。最近的研究表明GPR75与20-羟基二十碳四烯酸(20-HETE)和C-C基序趋化因子配体5(CCL5/趋化因子RANTES)等配体之间可能存在相互作用;然而,其确切的内源性配体仍未确定,目前GPR75被国际基础与临床药理学联合会(IUPHAR)归类为孤儿受体。关于GPR75去孤儿化的研究强调了它在疾病模型中的关键作用,特别是在代谢健康、葡萄糖调节以及神经和心血管系统的稳定性方面。然而,GPR75在不同病理条件下的信号通路仍需进一步研究。重要的是,正在进行的研究以GPR75为靶点进行药物开发,探索小分子抑制剂、抗体和基因沉默技术,使GPR75成为治疗相关疾病的一个有前景的GPCR靶点。这篇综述总结了GPR75去孤儿化研究的最新进展,研究了它在各种组织和系统中的功能,并强调了它与代谢、心血管和神经疾病的联系,从而为研究人员更好地理解该受体的生物学功能提供了参考资料。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2052/12071931/e62bfc0d48c5/ijms-26-04084-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验